Upstream Bio, Inc.UPBEarnings & Financial Report
TCI Co., Ltd. is a Taiwanese contract development and manufacturing organization (CDMO) specialising in the research, development and production of functional beverages, dietary supplements and skincare products. Headquartered in the Neihu Technology Park in Taipei, TCI evolved from an original trading company founded in 1980 into a CDMO group serving clients across Asia, Europe and North America, and is publicly traded on Taiwan's over-the-counter market under the code 8436.
Revenue
$607.0K
Gross Profit
N/A
Operating Profit
$-18.9M
Net Profit
$-16.0M
Gross Margin
N/A
Operating Margin
-3112.5%
Net Margin
-2634.6%
YoY Growth
N/A
EPS
$-6.96
Upstream Bio, Inc. Q3 FY2024 Financial Summary
Upstream Bio, Inc. reported revenue of $607.0K for Q3 FY2024, with a net profit of $-16.0M (-2634.6% margin).
Key Financial Metrics
| Total Revenue | $607.0K |
|---|---|
| Net Profit | $-16.0M |
| Gross Margin | N/A |
| Operating Margin | -3112.5% |
| Report Period | Q3 FY2024 |
Upstream Bio, Inc. Annual Revenue by Year
Upstream Bio, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $2.9M).
| Year | Annual Revenue |
|---|---|
| 2025 | $2.9M |
Upstream Bio, Inc. Quarterly Revenue & Net Profit History
Upstream Bio, Inc. results over the last 5 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $668.0K | — | $-42.5M | -6356.1% |
| Q3 FY2025 | $683.0K | +12.5% | $-33.7M | -4941.1% |
| Q2 FY2025 | $937.0K | — | $-40.0M | -4265.3% |
| Q1 FY2025 | $566.0K | — | $-27.3M | -4818.0% |
| Q3 FY2024 | $607.0K | — | $-16.0M | -2634.6% |
Income Statement
| Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|
| Revenue | $607000 | $566000 | $937000 | $683000 | $668000 |
| YoY Growth | N/A | N/A | N/A | 12.5% | N/A |
Balance Sheet
| Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|
| Assets | $232.7M | $456.2M | $420.5M | $391.2M | $353.8M |
| Liabilities | $12.1M | $10.6M | $11.8M | $12.6M | $14.0M |
| Equity | $-160.3M | $445.6M | $408.7M | $378.6M | $339.8M |
Cash Flow
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|
| Operating CF | $-41.2M | $-39.2M | $-22.2M | $-30.6M |